Maze Therapeutics
http://www.mazetx.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Maze Therapeutics
FTC Is Taking A Tougher Stance On Pharma, A Deputy Director Explains Why
Rahul Rao, the deputy director of the FTC Bureau of Competition, discussed the agency’s thinking on recent pharma deals that it viewed as anti-competitive.
FTC Is Taking A Tougher Stance On Pharma; A Deputy Director Explains Why
Deputy director of the Bureau of Competition Rahul Rao discussed the agency’s thinking on recent pharma deals that it viewed as anti-competitive.
Shionogi Still Hopeful For Xocova In US Despite Phase III Fail
Despite sales success in Japan and a fast track designation in the US, Shionogi’s oral COVID-19 therapeutic has missed statistical significance in a global Phase III trial in patients with mild to moderate symptoms.
Maze Finds A Way As Shionogi Signs On To Develop Pompe Drug
Months after an antitrust lawsuit challenged its deal with Sanofi and raised uncertainty about the future of MZE001, Maze secured a new partner for potentially the first oral Pompe disease drug.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- Genomics-Proteomics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice